Abstract: Systems, apparatuses, and methods are described herein for disease detection using an analyte-agnostic approach. Such systems, apparatuses, and methods can include using an array with hydrogels disposed on a substrate, where the hydrogels include one or more polymerized monomers and one or more photoinitiators or photocleavage products thereof. One or more samples including one or more unlabeled analytes can be contacted with an array of polymers. The samples disposed on the array can be incubated for a first predetermined period of time, and heated at a predetermined temperature for a second predetermined period of time. An imaging device (e.g., flatbed scanner) can be used to measure an amount of one or more colorimetric or luminescence signals produced by the array after the incubating and heating. A neural network trained using the samples can then be used to predict a diagnostic or disease class for the sample.

Abstract: The disclosed embodiments include detectable arrays, systems for diagnosing diseases, conditions, or disorders, and methods of making and using the same.

Abstract: A method and separation device for removing PCR inhibitors from whole blood or plasma/serum, is provided. The disclosed embodiments include the separation device; and system for removing PCR inhibitors and separating PCR inhibitors from nucleic acids, such as DNA or RNA, and the other components found in whole blood or plasma/serum samples, and methods of making and using the same, so that uncontaminated DNA/RNA is replicated. The separation device comprises: a receptacle for holding whole blood, serum or plasma samples; and a physical substrate for binding and removing one or more PCR inhibitors from the sample matrices, and glass capillary tubes. Physical substrates comprise, e.g. a crosslinked copolymer comprising acrylamide and N,N?-Methylenebisacrylamide, and one or more derivatives of acrylamide and acrylate with glycerol; and non-acrylamide based polymers such as sodium alginate or polyvinyl alcohol with agarose. And the receptacle comprises, e.g.

Abstract: The disclosed embodiments include detectable arrays, systems for diagnosing diseases, conditions, or disorders, and methods of making and using the same.

Abstract: A mobile communication device. The mobile communication device includes a baseband processor and an application processor. The application processor includes a modem proxy service module communicatively coupled to the baseband processor and an application management service module communicatively coupled to the modem proxy service module and configured to retrieve identification of a new operating mode. The application management service module is configured to direct appropriate components to initiate actions necessary to switch to the new mode, convey a request to the baseband processor to switch to the new mode, and switch the application processor to the new mode. The baseband processor is configured to convey notification to the application management service module that it completed the mode switch.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.